Promoters of Ajanta Pharma have revised their disclosures regarding the pledge of 66,32,651 equity shares to secure non-convertible debentures. The update, submitted to stock exchanges on July 7, 2026, specifies the entities in whose favor the encumbrance was created, naming 360 ONE Income Opportunities Fund series and 360 ONE Prime Ltd as the debenture holders, with CTL Trusteeship Limited acting as the security trustee. The original filing had only named the trustee.

The encumbrance was created on June 2, 2026, and June 30, 2026. The shares, representing 5.31% of the total share capital, were pledged by Aayush Agrawal Trust, Aayush Agrawal, and Gabs Investments Private Limited. The revision was made following a communication from BSE regarding a discrepancy in the earlier submission under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Pledge Details

The table below outlines the revised shareholding and encumbrance details for the promoters involved:

The total encumbered shares reported in the revised disclosure stand at 1,42,45,087 shares, or 11.40% of the total share capital. The equity share capital of Ajanta Pharma remains at ₹24,98,71,248, comprising 12,49,35,624 equity shares with a face value of ₹2 each.

Ajanta Pharma has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its manufacturing facility located in Paithan, Maharashtra. The inspection, conducted from 13 April 2026 to 21 April 2026, has been classified as Voluntary Action Indicated (VAI), signifying a favourable regulatory outcome for the company's facility.

USFDA Inspection Outcome

The VAI classification is one of three possible outcomes assigned by the USFDA following a facility inspection. It indicates that while the agency may have noted certain observations during the inspection process, no regulatory or administrative action is deemed necessary at this stage. This outcome is generally considered a positive result in the pharmaceutical industry, as it confirms the facility's compliance with USFDA standards.

Key Details of the Inspection

The following table summarises the key details related to the USFDA inspection report received by Ajanta Pharma:

Significance of VAI Classification

A Voluntary Action Indicated status from the USFDA reflects that the inspected facility meets the required manufacturing and quality standards as assessed by the regulatory authority. For pharmaceutical companies with US market exposure, receiving a VAI classification on an EIR underscores the facility's adherence to Current Good Manufacturing Practices (cGMP) and supports continued operations for the US market.